Listen now | Episode 215 Peter van der Velden joins Matt Cohen to discuss the dynamic changes within the life sciences sector and venture capital at large. He highlights the success factors in life sciences as a high-performing asset class and discusses the role of Canadian pension funds in supporting innovation. The episode also covers the transformative potential of GLP-1 drugs and AI's impact on drug discovery and medical technology.And John Ruffolo is back to talk about the US elections and tech news. (Note: this was recorded before the election on 11/5/24).
Transforming Healthcare Through Venture Capital: GLP-1 Drugs, AI, and the state of the CVCA with Peter van der Velden of Lumira Ventures
Transforming Healthcare Through Venture…
Transforming Healthcare Through Venture Capital: GLP-1 Drugs, AI, and the state of the CVCA with Peter van der Velden of Lumira Ventures
Listen now | Episode 215 Peter van der Velden joins Matt Cohen to discuss the dynamic changes within the life sciences sector and venture capital at large. He highlights the success factors in life sciences as a high-performing asset class and discusses the role of Canadian pension funds in supporting innovation. The episode also covers the transformative potential of GLP-1 drugs and AI's impact on drug discovery and medical technology.And John Ruffolo is back to talk about the US elections and tech news. (Note: this was recorded before the election on 11/5/24).